Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:BDSI NASDAQ:MORF NASDAQ:SVA NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.01$5.90$3.21▼$6.78$1.21B0.673.34 million shs3.43 million shsBDSIBioDelivery Sciences International$5.59$5.58$2.50▼$5.62$577.05M0.563.34 million shs2.09 million shsMORFMorphic$56.99$56.76$19.34▼$57.00$2.85B1.491.27 million shs400 shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.61N/AN/AVKTXViking Therapeutics$33.05-2.5%$29.27$18.92▼$81.73$3.81B0.645.46 million shs3.09 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+1.50%-3.65%-24.21%+11.33%-17.05%BDSIBioDelivery Sciences International0.00%0.00%0.00%0.00%0.00%MORFMorphic0.00%0.00%0.00%0.00%0.00%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics+1.04%+5.05%+36.68%+10.46%-48.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.01$5.90$3.21▼$6.78$1.21B0.673.34 million shs3.43 million shsBDSIBioDelivery Sciences International$5.59$5.58$2.50▼$5.62$577.05M0.563.34 million shs2.09 million shsMORFMorphic$56.99$56.76$19.34▼$57.00$2.85B1.491.27 million shs400 shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.61N/AN/AVKTXViking Therapeutics$33.05-2.5%$29.27$18.92▼$81.73$3.81B0.645.46 million shs3.09 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+1.50%-3.65%-24.21%+11.33%-17.05%BDSIBioDelivery Sciences International0.00%0.00%0.00%0.00%0.00%MORFMorphic0.00%0.00%0.00%0.00%0.00%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics+1.04%+5.05%+36.68%+10.46%-48.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.91Moderate Buy$11.70133.53% UpsideBDSIBioDelivery Sciences International 0.00N/AN/AN/AMORFMorphic 0.00N/AN/AN/ASVASinovac Biotech 0.00N/AN/AN/AVKTXViking Therapeutics 2.86Moderate Buy$86.42161.47% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, MORF, SVA, VKTX, and BDSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ARDXArdelyxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VKTXViking TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/29/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.009/27/2025ARDXArdelyxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VKTXViking TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/22/2025VKTXViking TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.009/3/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$14.009/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy8/19/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.008/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$8.00 ➝ $9.008/5/2025ARDXArdelyxUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M3.62N/AN/A$0.73 per share6.86BDSIBioDelivery Sciences International$166.70M3.46$0.36 per share15.42$1.90 per share2.94MORFMorphic$520K5,490.11N/AN/A$12.31 per share4.63SVASinovac Biotech$448.27M1.44$0.17 per share38.95$120.83 per share0.05VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A16.16N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)BDSIBioDelivery Sciences International$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/AMORFMorphic-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/ASVASinovac Biotech-$99.92MN/A0.00∞N/AN/AN/AN/AN/AVKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest ARDX, MORF, SVA, VKTX, and BDSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025ARDXArdelyx-$0.07N/AN/AN/A$100.44 millionN/A10/22/2025Q3 2025VKTXViking Therapeutics-$0.71N/AN/AN/AN/AN/A8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ABDSIBioDelivery Sciences InternationalN/AN/AN/AN/AN/AMORFMorphicN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03BDSIBioDelivery Sciences International0.292.452.17MORFMorphicN/A24.1324.13SVASinovac BiotechN/AN/AN/AVKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%BDSIBioDelivery Sciences International64.40%MORFMorphic94.25%SVASinovac BiotechN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%BDSIBioDelivery Sciences International9.98%MORFMorphic25.60%SVASinovac Biotech12.79%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableBDSIBioDelivery Sciences International200103.23 million92.93 millionOptionableMORFMorphic10050.09 million37.27 millionOptionableSVASinovac Biotech3,26199.64 million86.89 millionOptionableVKTXViking Therapeutics20112.44 million107.84 millionOptionableARDX, MORF, SVA, VKTX, and BDSI HeadlinesRecent News About These CompaniesViking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to NoteOctober 14 at 6:51 PM | zacks.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.5% - Should You Sell?October 14 at 5:40 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 1% - What's Next?October 13 at 5:57 PM | marketbeat.comIFP Advisors Inc Acquires 10,048 Shares of Viking Therapeutics, Inc. $VKTXOctober 13 at 6:08 AM | marketbeat.comM&A Speculation Fuels Volatility in Viking Therapeutics SharesOctober 12 at 4:07 AM | aktiencheck.deAViking Therapeutics, Inc. $VKTX Shares Acquired by Blair William & Co. ILOctober 12 at 4:00 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 4.1% - What's Next?October 10, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Purchases New Stake in Viking Therapeutics, Inc. $VKTXOctober 10, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 8.1% - Should You Buy?October 10, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 9, 2025 | americanbankingnews.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of "Moderate Buy" by BrokeragesOctober 9, 2025 | marketbeat.comViking Therapeutics' (VKTX) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 8, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 2.6% - Here's WhyOctober 8, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 2.3% - Here's WhyOctober 7, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 8.6% - Here's What HappenedOctober 6, 2025 | marketbeat.comWhy Viking Therapeutics (VKTX) Is Up 15.1% After Acquisition Buzz and Analyst Focus on Its PipelineOctober 6, 2025 | finance.yahoo.comViking Therapeutics:Â A Speculative BuyOctober 4, 2025 | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 6.6% - What's Next?October 3, 2025 | marketbeat.comViking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to KnowOctober 2, 2025 | zacks.comViking Therapeutics (NASDAQ:VKTX) Shares Up 1.9% - Should You Buy?October 2, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 4.1% - Should You Buy?October 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Biotech Breakouts: 3 Stocks With Massive Upside PotentialBy Chris Markoch | September 17, 2025ARDX, MORF, SVA, VKTX, and BDSI Company DescriptionsArdelyx NASDAQ:ARDX$5.01 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$5.01 +0.00 (+0.10%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.BioDelivery Sciences International NASDAQ:BDSIBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.Morphic NASDAQ:MORFMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Sinovac Biotech NASDAQ:SVASinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.Viking Therapeutics NASDAQ:VKTX$33.05 -0.86 (-2.54%) Closing price 04:00 PM EasternExtended Trading$33.17 +0.13 (+0.38%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
